GVB Biopharma, a leading hemp cannabinoid producer, announced today that its research and development team has identified and isolated a previously unstudied cannabinoid called cannabicitran, or CBT
| LAS VEGAS, Dec. 9, 2019 /PRNewswire/ -- GVB Biopharma, a leading hemp cannabinoid producer, announced today that its research and development team has identified and isolated a previously unstudied cannabinoid called cannabicitran, or CBT. This group of scientists, comprised of alumni from the world’s leading pharmaceutical companies, will be able to study the structure, function and potential benefits of CBT in extensive detail.
What little is known about CBT is that it is found in highest concentrations in the distillates from the Type III flowers of the cannabis plant, which have high levels of cannabidiol (CBD) and low levels of tetrahydrocannabinol (THC). However, compared to most other cannabinoids, it is found in relatively low concentrations. Chemically, CBT is classified as a diether, which means that it has the same chemical relationship with CBD as CBD has with THC. Since it has the special quality of being the last cannabinoid retained on the chromatography column that chemists use to identify compounds, chemists may be able to use CBT as a marker for the end of all the known cannabinoids identified from a sample. Precious few research studies have been published on the health effects of CBT. One study, performed over 35 years ago by longtime cannabinoid researcher Mahmoud ElSohly, was promising: CBT was found to reduce pressure within the eyes in rabbits, making CBT a potential treatment for glaucoma and other conditions. With their new identification and isolation of CBT, the research and development team at GVB Biopharma have unearthed this unstudied cannabinoid. These pioneering scientists are poised to significantly expand the public knowledge base on cannabicitran and get a clear-eyed view of its significance. GVB Biopharma utilizes a commitment to exacting principles to deliver rigorously tested hemp and cannabinoid products to the discerning consumer. With its state-of-the-art facilities for hemp processing in Oregon and white-label consumer product manufacturing in Las Vegas, GVB Biopharma adheres to the highest standards of product quality. From testing the genetic stability of seeds, to verifying the cannabinoid capacity of its plants, to checking the purity of the distilled oil, the integrity of the GVB Biopharma process is reflected in every product.
SOURCE GVB Biopharma |
View original content to download multimedia:
